TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Timing of Coronary Angiography in NSTE-ACS With ADHF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age more than 18 years old~2. NSTE-ACS\*~3. Pulmonary congestion or edema on chest X-ray~   * The definition of NSTE-ACS~Among patients with typical angina, dyspnea or chest discomfort without definite non-cardiac causes, at least 1 presentations of angina that suggest a NSTE-ACS:~1. Rest angina, which is usually more than 20 minutes in duration~2. New onset angina that markedly limits physical activity~3. Increasing angina that is more frequent, longer in duration, or occurs with less exertion than previous angina~A 12-lead electrocardiogram should have no ST-segment elevation. Cardiac troponin may elevate (non-ST-segment elevation myocardial infarction) or not elevate (unstable angina pectoris).~Exclusion Criteria:~1) Cardiogenic shock\* 2) Heart failure of other causes rather than NSTE-ACS 3) Terminal malignancy 4) Life expentancy \< 1 year 5) Pregnancy or lactation~\* The definition of cardiogenic shock All these criteria should be met~1. Systolic blood pressure \< 90 mmHg for 30 minutes, or needing inotropics or vasopressor to maintain systolic blood pressure \> or = 90 mmHg~2. Pulmonary congestion on chest X-ray or increased left ventricular filling pressure by cardiac catheterization~3. At least one criteria of organ dysfunction - mental obtundation, clammy ski, ogliuria, renal dysfunction, increased level of blood lactate

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate coronary angiography group (Type: EXPERIMENTAL): Immediate coronary angiography group will routinely receive coronary angiography within 2 hours after randomization.
- Delayed coronary angiography group (Type: ACTIVE_COMPARATOR): Delayed coronary angiography group will receive coronary angiography during hospitalization after stabilization of symptoms and signs of heart failure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with systemic lupus erythematosus (SLE) who participated and satisfactorily completed their Week 52 evaluation in Study U2971g.~* For partial clinical response (PCR) or nonclinical response (NCR), active disease at screening as defined by one or more domains with a British Isles Lupus Assessment Group (BILAG) A score or 2 or more domains with a BILAG B score.~Exclusion Criteria:~* Subjects who were withdrawn from study U2971g because of protocol non-compliance or for safety issues.~* Any safety concern potentially attributed to rituximab that in the investigator's opinion would jeopardize subject safety.~* Subjects who were withdrawn from study U2971g and received rituximab rescue therapy outside of the protocol.~* Subjects, that in the investigator's opinion, have not demonstrated any clinical improvement by Week 52 in study U2971g and in whom the proposed therapy would represent risk without benefit.~* Unstable subjects with thrombocytopenia experiencing or at high risk for developing clinically significant bleeding or organ dysfunction requiring therapies such as plasmapheresis or acute blood or platelet transfusions.~* Pregnant women or nursing (breastfeeding) mothers.~* History of severe, allergic, or anaphylactic reactions to humanized or murine monoclonal antibodies.~* Known active infection of any kind (excluding fungal infection of nail beds) or any major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 8 weeks of screening or oral antibiotics within 2 weeks prior to screening.~* History of cancer, including solid tumors, hematological malignancies, and carcinoma in situ.~* Major surgery within 4 weeks prior to screening.~* Intolerance or contraindication to oral or IV corticosteroids.~* Positive hepatitis B surface antigen (BsAg) or hepatitis C serology.~* Receipt of a live vaccine within 28 days prior to treatment.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab 1000 mg (Type: EXPERIMENTAL): Participants will receive rituximab 1000 mg intravenously twice, 14 days apart at study entry and again 6 months later. Participants will also receive methylprednisolone 100 or 125 mg IV, acetaminophen 1000 mg orally, and diphenhydramine 50 mg orally prior to study drug infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Benefits of the Closed Loop Stimulation in Sinus Node Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Class I or II recommendations for permanent pacing due to SND, with or without AV block according to the current guidelines;~* Patients for whom dual-chamber pacing is indicated or preferred;~* Patients with an optimized and stable antiarrhythmic medical therapy at the time of enrolment;~* Closed Loop Stimulation function was not previously activated;~* No stroke events from implant;~* Patient implanted for the first time;~Exclusion Criteria:~* Permanent AF (PermAF)~* NYHA Class IV Heart Failure~* Stage V kidney dysfunction~* Any indication to Cardiac Resynchronization Therapy (CRT)~* Life expectancy \< 1~* Minors~* Pregnant or breast-feeding patients~* Participation in another interventional trial~* Atrial fibrillation ablation (left pulmonary veins) or other cardiac surgery \< 3 m

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active group - CLS ON (Type: EXPERIMENTAL): Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON; Intervention: DDD+CLS
- Control group - CLS OFF (Type: ACTIVE_COMPARATOR): Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Home Outpatient Monitoring and Engagement to Predict HF Exacerbation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Outpatient and cared for by a PINNACLE Registry practice~2. Age ≥ 18 years old~3. Has a diagnosis of HF in the PINNACLE Registry/Medical Record~4. Seen by PINNACLE practice within the last 12 months~5. Has an LVEF ≤40% on their last data entry (within 1 year) in the PINNACLE Registry~6. NYHA Class II-IV by self-report~7. Has had a hospitalization for HF in the previous 6 months by self-report~8. Owns an Android or iOS smartphone, within Verizon cellular coverage zone in order to allow for data submission.~9. Sleep in the same bed at least 5 days per week~10. Willingness to complete the required surveys, measurements and study activities.~Exclusion Criteria:~1. Home oxygen use~2. Current or planned ventricular assist device~3. Previously or currently on a heart transplant list~4. Chronic dialysis~5. A diagnosis of any cancer and undergoing active treatment~6. In hospice or palliative care~7. Planned surgery/procedure in the next 3 months~8. Planned extended time away from home (\>2 weeks) in the next 3 months~9. Living in a skilled nursing facility or other chronic care facility~10. Pregnancy or planned pregnancy in the next 3 months~11. Inability or unwillingness to consent and/or follow requirements of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Training Set (Type: None): n = 333
- Validation Set (Type: None): n = 167

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ethanol in the Prevention of Central Venous Catheter Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* older than 18 years old~* Signed informed consent~* central Venous catheter more than 48 hours placed~Exclusion Criteria:~* pregnancy~* denial Informed consent Form~* ethanol intolerance~* Liver cirrhosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ethanol (Type: EXPERIMENTAL): Every three day lock using Ethanol in all the lumen of the Catheter
- Heparine (Type: ACTIVE_COMPARATOR): Every three day lock using Heparine in all the lumen of the Catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Menstrual Cycle on Central Nervous System (CNS) Processing of Gut Stimuli in Irritable Bowel Syndrome (IBS) and Control

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* controls - normal bowel function~* Irritable bowel syndrome - Rome II criteria~* Normal menstrual cycle~Exclusion Criteria:~* irregular menses~* pregnancy~* use of psychotropic medication~* claustrophobia~* metal implants~* metal in eyes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- control (Type: None): subjects with no irritable bowel syndrome or gastrointestinal complaints and regular menstrual cycle.
- IBS (Type: None): women with IBS symptoms and normal menstrual cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Myocardial Disease in Man Using Novel Non-invasive Diagnostic Tools

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Over 18 years~* Have provided consent~Risk factor patients also require:~* Hypertension \> 2 years~* Diabetes \> 2 years~* Known ischemia, TIA, or stroke~* Arrhythmia; or reduced renal function (eGFR\<50 ml/min)~Heart Failure patients also require:~* LVEF \<40%~* Receiving standard medication for the treatment of symptomatic systolic heart failure with an NYHA Class of II-IV.~Exclusion Criteria:~Health patients (must not have any of the following):~1. Cardiovascular disease~2. Receiving cardiovascular medication~3. Not in normal sinus rhythm (also required for HF patients)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Healthy subjects (with no evidence of cardiovascular disease).
- 2 (Type: EXPERIMENTAL): Patients with risk factors for heart failure
- 3 (Type: EXPERIMENTAL): Patients with heart failure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. MDS and 5% or more marrow blasts, or IPSS risk intermediate 1-2 or high risk; or chronic myelomonocytic leukemia. Patients must have failed therapy with azacytidine.~2. Performance status 0-2 (ECOG scale); adequate hepatic (bilirubin \< 2 mg/dl) and renal functions (creatinine \<2mg/dl); New York Heart Association (NYHA)cardiac status III-IV excluded.~3. Signed informed consent.~4. No prior intensive combination chemotherapy or high-dose ara-C (\>/= 1g/m\*2 per dose). Prior biologic therapies, targeted therapies and single agent chemotherapy allowed.~5. Patients must have been off chemotherapy for 2 weeks prior to entering this study and recovered from the toxic effects of that therapy, unless there is evidence of rapidly progressive disease. Use of hydroxyurea for patients with rapidly proliferative disease is allowed for the first two weeks on therapy.~Exclusion Criteria:~1. Nursing and pregnant females are excluded. Patients of childbearing potential should practice effective methods of contraception. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.~2. Patients with active and uncontrolled infections.~3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine (Type: EXPERIMENTAL): 20 mg/m2 by vein (IV) over 1 hour daily x 5 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preliminary Study of Feasibility of Arthrodesis Scapula-humeral Under Arthroscopy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient having a deficit scapula-humeral mobility~* Impossibility of being operated for a preserving nervous surgery~* Patient affiliation with a social security~* Patient who signed inform consent~Exclusion Criteria:~* Patient with No mobility in all the articulations of the shoulder~* Callus malunion of the higher end of the humerus or the glen of the scapula~* Unable to sign an inform consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- shoulder arthroscopy arthrodesis (Type: EXPERIMENTAL): The shoulder surgery will be realized under arthroscopy only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent has been obtained.~2. Male or female patients with a diagnosis of asthma and/or COPD whose budesonide-formoterol DPI was switched to another budesonide-formoterol DPI at pharmacy between 1st July 2018 and 1st March 2019 (referred to as the eligible switch).~3. Age ≥12 years at time of switch.~4. Treated with budesonide-formoterol for at least 12 months before the eligible switch (pre-switch period) and 12 months after the eligible switch (post-switch period). Re-switch(es) of inhaler are allowed during the post-switch period.~Exclusion Criteria:~1. Patient has declined participation in the study or failed to respond to the invitation to participate.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intestinal Phosphate Transporter Expression in CKD Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Upper endoscopy for suspected or known esophageal or gastric pathology~* Upper endoscopy for screening purposes~* Written consent to take part in the study~Exclusion Criteria:~* Food intake within 8 hours prior to the endoscopy~* Major duodenal pathology, in particular duodenitis or duodenal ulcers or tumor~* Contraindication to duodenal biopsy such as bleeding disorder~* Treatment with medication known to regulate the expression or activity of intestinal phosphate transporters (e.g. nicotinamide)~* Kidney transplant patients~* Alcohol or drug abuse~* Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study~* Participation in a parallel clinical trial~* Subjects who are in any state of dependency to the sponsor or the investigators~* Employees of the sponsor or the investigators~* Subjects who have been committed to an institution by legal or regulatory order

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- normal renal function (Type: EXPERIMENTAL): Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
- CKD stage 3-5 (not on dialysis) (Type: EXPERIMENTAL): Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
- on dialysis (Type: EXPERIMENTAL): Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Insulin Drip Protocols in Labor: A Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* a. Pregnant patients with either pre-existing diabetes or gestational diabetes type A2 who require insulin for euglycemia during labor and delivery~Exclusion Criteria:~* a. Those patients who decline participation~* b. Patients less than age 18 at the time of enrollment will be excluded to protect this vulnerable patient population c. Those patients who cannot be consented d. Patients scheduled for cesarean delivery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Protocol A (Type: ACTIVE_COMPARATOR): Our current standard during labor
- Protocol B (Type: ACTIVE_COMPARATOR): Another commonly accepted alternative for insulin drip management during labor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~To be eligible for inclusion into the study, a patient must meet the following criteria:~* Subject has clinically confirmed diagnosis of active Notalgia Paresthetica;~* Subject has a history of chronic pruritus due to Notalgia Paresthetica;~* Subject has moderate to severe pruritus;~* Female subject is not pregnant or nursing during any period of the study.~Key Exclusion Criteria:~A patient will be excluded from the study if any of the following criteria are met:~* Subject has pruritus attributed to a cause other than Notalgia Paresthetica;~* Subject has any clinically significant medical condition or physical/laboratory/ECG/vital signs abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Difelikefalin 2.0 mg tablets (Type: ACTIVE_COMPARATOR): Oral difelikefalin 2.0 mg tablet administered twice daily
- Difelikefalin 1.0 mg tablets (Type: ACTIVE_COMPARATOR): Oral difelikefalin 1.0 mg tablet administered twice daily
- Difelikefalin 0.25 mg tablets (Type: ACTIVE_COMPARATOR): Oral difelikefalin 0.25 mg tablet administered twice daily
- Placebo tablets (Type: PLACEBO_COMPARATOR): Oral placebo tablet administered twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy